Business Wire: AtaCor Medical to Present Preliminary Results from First-in-Human Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study AtaCor Medical to Present Preliminary Results from First-in-Human Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study Business Wire: AtaCor Medical Completes Enrollment in its Initial Acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study. AtaCor Medical Completes Enrollment in its Initial Acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Study SAN FRANCISCO — An implantable cardioverter defibrillator (ICD) with a lead system that inserts just below the sternum performed promisingly in a recent early experience that sets the stage for a more ...
The subcutaneous implantable cardioverter–defibrillator (ICD) was designed to avoid complications related to the transvenous ICD lead by using an entirely extrathoracic placement. Evidence comparing ... The indications for ICD implantation continue to expand; however, these devices are associated with complications related to the implantation procedure itself and morbidity caused by the normal and ...
